{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T04:08:51Z","timestamp":1729397331255,"version":"3.27.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,19]]},"DOI":"10.7759\/cureus.71846","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T10:57:29Z","timestamp":1729335449000},"source":"Crossref","is-referenced-by-count":0,"title":["Essential Thrombocythemia Possible Cause of Ischemic Cerebrovascular Disease: A Case Report"],"prefix":"10.7759","author":[{"given":"Ibrahim","family":"Korucu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed Fatih","family":"Ciril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.35","article-title":"An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms","volume":"28","author":"Tefferi A","year":"2014","unstructured":"Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014, 28:1407-13. 10.1038\/leu.2014.35","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(05)71142-9","article-title":"Cancer genome project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter EJ","year":"20051925","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al.. Cancer genome project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 20051925, 365:1054-61. 10.1016\/s0140-6736(05)71142-9","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy","volume":"27","author":"Campbell PJ","year":"2009","unstructured":"Campbell PJ, Bareford D, Erber WN, et al.. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol. 2009, 27:2991-9. 10.1200\/JCO.2008.20.3174","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100714","article-title":"Current management strategies for polycythemia vera and essential thrombocythemia","volume":"42","author":"Guglielmelli P","year":"2020","unstructured":"Guglielmelli P, Vannucchi AM. Current management strategies for polycythemia vera and essential thrombocythemia. Blood Rev. 2020, 42:100714. 10.1016\/j.blre.2020.100714","journal-title":"Blood Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000516471","article-title":"Antithrombotic management in ischemic stroke with essential thrombocythemia: current evidence and dilemmas","volume":"30","author":"Das S","year":"2021","unstructured":"Das S, Deb A, Pal T. Antithrombotic management in ischemic stroke with essential thrombocythemia: current evidence and dilemmas. Med Princ Pract. 2021, 30:412-21. 10.1159\/000516471","journal-title":"Med Princ Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071746","article-title":"Essential thrombocythemia and acquired von Willebrand syndrome: the shadowlands between thrombosis and bleeding","volume":"12","author":"Awada H","year":"2020","unstructured":"Awada H, Voso MT, Guglielmelli P, Gurnari C. Essential thrombocythemia and acquired von Willebrand syndrome: the shadowlands between thrombosis and bleeding. Cancers (Basel). 2020, 12:10.3390\/cancers12071746","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2224-8","article-title":"Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (\u00d6GHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.)","volume":"93","author":"Kreher S","year":"2014","unstructured":"Kreher S, Ochsenreither S, Trappe RU, et al.. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (\u00d6GHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol. 2014, 93:1953-63. 10.1007\/s00277-014-2224-8","journal-title":"Ann Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American","volume":"50","author":"Powers WJ","year":"2019","unstructured":"Powers WJ, Rabinstein AA, Ackerson T, et al.. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American. Stroke. 2019, 50:e344-418. 10.1161\/STR.0000000000000211","journal-title":"Stroke"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan WN","year":"2014","unstructured":"Kernan WN, Ovbiagele B, Black HR, et al.. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2014, 45:2160-236. 10.1161\/STR.0000000000000024","journal-title":"Stroke"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24320","article-title":"Refining prognostication of thrombosis in ET","volume":"91","author":"Barbui T","year":"2016","unstructured":"Barbui T. Refining prognostication of thrombosis in ET. Am J Hematol. 2016, 91:361-3. 10.1002\/ajh.24320","journal-title":"Am J Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70515","article-title":"Cardioembolic artery of percheron infarction","volume":"16","author":"Llapitan LL","year":"2024","unstructured":"Llapitan LL, Pedregosa BC, Navarro JC. Cardioembolic artery of percheron infarction. Cureus. 2024, 16:9. 10.7759\/cureus.70515","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui T","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, et al.. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011, 29:761-70. 10.1200\/JCO.2010.31.8436","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo S","year":"1995","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995, 332:1132-6. 10.1056\/NEJM199504273321704","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial","volume":"110","author":"Finazzi G","year":"2000","unstructured":"Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000, 110:577-83. 10.1046\/j.1365-2141.2000.02188.x","journal-title":"Br J Haematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison CN","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, et al.. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005, 353:33-45. 10.1056\/NEJMoa043800","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison CN","year":"2017","unstructured":"Harrison CN, Mead AJ, Panchal A, et al.. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017, 130:1889-97. 10.1182\/blood-2017-05-785790","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/308786-essential-thrombocythemia-possible-cause-of-ischemic-cerebrovascular-disease-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T10:57:30Z","timestamp":1729335450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/308786-essential-thrombocythemia-possible-cause-of-ischemic-cerebrovascular-disease-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.71846","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,19]]}}}